Today: 9 April 2026
Subscribe
Browse Category

NASDAQ:OLMA 18 November 2025 - 29 January 2026

Olema Pharmaceuticals (OLMA) stock jumps 6% in a weak market — what to watch next

Olema Pharmaceuticals (OLMA) stock jumps 6% in a weak market — what to watch next

Olema Pharmaceuticals shares rose 5.8% to $25.99 Thursday afternoon, adding about $127 million in market value as broader indexes fell. Trading volume reached 926,000 shares. No new company news emerged, but traders are watching for Olema’s March update and progress on its late-stage palazestrant trial. The company reported over $500 million in cash and equivalents as of Dec. 31, 2025.
29 January 2026
··
OLMA stock jumps 10% into JPMorgan week — what to watch for Olema Pharmaceuticals

OLMA stock jumps 10% into JPMorgan week — what to watch for Olema Pharmaceuticals

Olema Pharmaceuticals shares jumped 9.8% to $28.08 Friday, with 2.5 million shares traded ahead of the CEO’s Jan. 13 presentation at the J.P. Morgan Healthcare Conference. Citi, UBS, and Piper Sandler issued bullish ratings and price targets up to $60, citing upcoming trial data and potential catalysts. Olema raised $218.5 million in November. The company has no approved products and is advancing two breast cancer drug candidates.
11 January 2026
·
Olema Pharmaceuticals (OLMA) Stock: Weekend Read Ahead on the Pullback, Insider Sales, and Wall Street Targets Before Monday’s Open

Olema Pharmaceuticals (OLMA) Stock: Weekend Read Ahead on the Pullback, Insider Sales, and Wall Street Targets Before Monday’s Open

Olema Pharmaceuticals shares closed at $26.23 Friday, down 4.44%, capping a roughly 28% drop from mid-December highs. Year-to-date, the stock remains up about 350%. No new company news or filings appeared in the past 48 hours. Recent insider Form 4 filings show large option exercises and share sales by Director Ian T. Clark and Chief Medical Officer Naseem Zojwalla.
28 December 2025
··
Olema Pharmaceuticals (OLMA) Stock Update: Weekend Snapshot, Insider Sales, Analyst Targets, and Key Catalysts Ahead of Monday

Olema Pharmaceuticals (OLMA) Stock Update: Weekend Snapshot, Insider Sales, Analyst Targets, and Key Catalysts Ahead of Monday

Olema Pharmaceuticals shares closed at $26.23 Friday, down $1.25, with about 828,000 shares traded in a thin, year-end session. The stock remains up 467.75% over the past six months. No major company news was released in the past 48 hours. Investors are watching recent insider filings and awaiting updates on Olema’s late-stage breast cancer program.
28 December 2025
Olema Pharmaceuticals (NASDAQ: OLMA) Stock: Latest News, Analyst Forecasts, and What’s Driving the Volatility on December 19, 2025

Olema Pharmaceuticals (NASDAQ: OLMA) Stock: Latest News, Analyst Forecasts, and What’s Driving the Volatility on December 19, 2025

Olema Pharmaceuticals (OLMA) fell 6.2% to $28.89 intraday Friday on Nasdaq, after opening at $31.22 and swinging between $31.95 and $28.89. No new company news was released; the move follows heightened volatility since Roche’s positive Phase 3 SERD data in November and Olema’s $190 million public offering.
19 December 2025
···
Olema Pharmaceuticals (OLMA) Stock Hits New 52‑Week High on December 10, 2025: What Investors Need to Know

Olema Pharmaceuticals (OLMA) Stock Hits New 52‑Week High on December 10, 2025: What Investors Need to Know

Olema Pharmaceuticals (NASDAQ: OLMA) surged over 11% to $29.68 on December 10, 2025, hitting a new 52-week high amid heavy trading. The rally followed positive Phase 3 data from Roche’s breast cancer drug trial, which boosted confidence in Olema’s own SERD candidate. Year-to-date, OLMA shares have climbed over 400%, with market cap reaching $2.37 billion.
10 December 2025
·
Olema Pharmaceuticals (OLMA) Stock: Latest News, Forecast & Analysis as of December 9, 2025

Olema Pharmaceuticals (OLMA) Stock: Latest News, Forecast & Analysis as of December 9, 2025

Olema Pharmaceuticals shares traded at $26–27 on December 9, up over 800% from their 52-week low but 12% below the recent high. The stock surged after Roche’s positive Phase 3 results for a similar breast cancer drug, triggering analyst upgrades and price target hikes. Market capitalization now stands near $2–2.2 billion. Analyst 12-month targets range from $20 to $55, with most rating the stock a strong buy.
9 December 2025
··
Olema Pharmaceuticals (OLMA) Soars Over 200% After Roche Breast Cancer Trial Win — What It Means for Palazestrant and Investors on November 18, 2025

Olema Pharmaceuticals (OLMA) Soars Over 200% After Roche Breast Cancer Trial Win — What It Means for Palazestrant and Investors on November 18, 2025

Olema Pharmaceuticals shares surged as much as 220% in pre-market trading on November 18 after Roche announced a Phase 3 win for its oral SERD giredestrant in early-stage breast cancer. The spike was driven by investor read-through to Olema’s similar drug palazestrant, not new Olema data. Volume hit 13.4 million shares, far above average. Shares later retreated toward the low-$20s during regular trading.
18 November 2025
·····

Stock Market Today

  • SPDR EURO STOXX 50 ETF (FEZ) Sees $197.2M Outflow, Shares Decline 4.2%
    April 9, 2026, 11:45 AM EDT. The SPDR EURO STOXX 50 ETF (FEZ) experienced a notable outflow of approximately $197.2 million, a 4.2% decrease in shares outstanding week over week, dropping from 71 million to 68 million units. FEZ last traded at $65.03, below its 52-week high of $69.44 but above the low of $50.46. ETFs like FEZ issue units that can be created or redeemed depending on investor demand; large outflows often signal selling of underlying assets. Monitoring such changes helps assess market sentiment towards European equities captured by FEZ.

Latest article

Salesforce Stock Hits Fresh 52-Week Low Despite AI Growth and $50 Billion Buyback

Salesforce Stock Hits Fresh 52-Week Low Despite AI Growth and $50 Billion Buyback

9 April 2026
Salesforce shares hit a new 52-week low Thursday, dropping 3.7% to $169.76 despite reporting 12% revenue growth and strong demand for its AI products. The broader software sector continued to slide, with the S&P 500 software and services index down about $1 trillion since January. Salesforce raised its buyback authorization to $50 billion and increased its dividend to 44 cents a share.
ServiceNow Stock Hits Fresh 52-Week Low as Analysts Cut Targets Ahead of Earnings

ServiceNow Stock Hits Fresh 52-Week Low as Analysts Cut Targets Ahead of Earnings

9 April 2026
ServiceNow shares dropped 5.1% to $92.45 by 10:20 a.m. EDT Thursday, hitting a new 52-week low after analysts at Stifel, BTIG, and Goldman Sachs cut price targets citing weak federal spending and limited 2026 growth. The company announced it will integrate AI, data, security, and governance into all products ahead of first-quarter results due April 22.
SoFi Technologies Stock Slips as Wall Street Cuts Targets Ahead of Q1 Earnings

SoFi Technologies Stock Slips as Wall Street Cuts Targets Ahead of Q1 Earnings

9 April 2026
SoFi Technologies shares fell 1.9% to $16.18 Thursday after KBW and Wells Fargo cut price targets ahead of first-quarter results due April 29. The moves follow Muddy Waters’ short position and claims of accounting issues, which SoFi denies. Affirm and LendingClub also traded lower. Barclays and other banks have trimmed targets as concerns mount over credit quality and sector valuations.
Tesla revives cheaper EV bet with compact SUV plan in China after sales strain

Tesla revives cheaper EV bet with compact SUV plan in China after sales strain

9 April 2026
Tesla is developing a smaller, cheaper electric SUV to be built first in Shanghai, sources said. The new model would cost less than the Model 3 and be smaller than the Model Y. Tesla produced 408,386 vehicles but delivered only 358,023 in Q1, as U.S. demand weakened and competition increased. Shares fell 0.8% Thursday.
Grab Holdings Bets on AI as Group Ride Tool Targets 40% Lower Fares

Grab Holdings Bets on AI as Group Ride Tool Targets 40% Lower Fares

9 April 2026
Grab Holdings launched 13 new AI-powered products in Jakarta, including a “Group Ride” feature that can cut fares by up to 40% for shared routes. CEO Anthony Tan said the tools aim to offset rising fuel costs and support demand as households tighten spending. The company’s 2026 revenue and profit forecasts remain below analyst expectations. Grab’s $600 million deal to buy Foodpanda Taiwan is pending regulatory approval.
Go toTop